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The guanine nucleotide exchange factor CNrasGEF activates Ras
in response to cAMP and cGMP
N. Pham*, I. Cheglakov*, C.A. Koch†‡, C.L. de Hoog†, M.F. Moran†§ and D. Rotin*
Small GTPase proteins such as Ras are key regulators
of cellular proliferation and are activated by guanine
nucleotide exchange/releasing factors (GEFs/GRFs).
Three classes of Ras GRFs have been identified to date,
represented by Sos1/2, Ras-GRF1/2 and Ras-GRP. Here,
we describe a novel candidate Ras activator, cyclic
nucleotide rasGEF (CNrasGEF), which contains CDC25,
Ras exchange motif (REM), Ras-association (RA), PDZ
and cNMP (cAMP/cGMP) binding (cNMP-BD) domains,
two PY motifs and a carboxy-terminal SxV sequence.
CNrasGEF can activate Ras in vitro, and it binds cAMP
directly via its cNMP-BD. In cells, CNrasGEF activates
Ras in response to elevation of intracellular cAMP or
cGMP, or treatment with their analogues 8-Br-cAMP or
8-Br-cGMP, independently of protein kinases A and G
(PKA and PKG). This activation is prevented in
CNrasGEF lacking its CDC25 domain or cNMP-BD.
CNrasGEF can also activate the small GTPase Rap1 in
cells, but this activation is constitutive and independent
of cAMP. CNrasGEF is expressed mainly in the brain and
is localized at the plasma membrane, a localization
dependent on the presence of intact PDZ domain but
not the SxV sequence. These results suggest that
CNrasGEF may directly connect cAMP-generating
pathways or cGMP-generating pathways to Ras.
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Results and discussion
CNrasGEF was isolated as part of our search for proteins
that bind to the WW domains of the ubiquitin protein ligase
Nedd4 [1]. A 450 nucleotide murine fragment encoding two
PY motifs (xPPxY in the single-letter amino acid code) was
isolated that was 75% identical (95% similar) at the amino
acid level to the hypothetical gene product of the human
GenBank entry KIAA0313. We renamed KIAA0313 to
CNrasGEF, as it probably represents a novel class of Ras
GEFs. CNrasGEF is related to the budding yeast protein
Cdc25p and has several candidate domains, including, in
amino to carboxyl order: cNMP-BD, REM, PDZ and RA
domains, a Cdc25-related GEF domain, two PY motifs
responsible for binding to the Nedd4 WW domain, and a
carboxy-terminal SAV sequence conforming to PDZ-
binding motif consensus. The CNrasGEF Cdc25 domain is
similar to the Ras GEF regions in Sos1/2, GRF1/2 and
GRP, as well as in Rap GEFs such as Epac [2,3], but it con-
tains a unique insertion (see Supplementary material) [4].
The PDZ domain of CNrasGEF appears most similar to
those of Lin7, PTP-BAS, PSD-95 and Dlg (see Supplemen-
tary material). The cNMP-BD of CNrasGEF is similar to
the cAMP-binding region of PKA and cAMP GEFs [2,3]
and to the cGMP-binding region of PKG and cyclic-
nucleotide-gated K+ channels, although it lacks conserva-
tion of the AA or TA within the R(A/T)A motif found in
PKA (and Epac) or in PKG, respectively (see Supplemen-
tary material). The arginine in the motif plays a key role in
cyclic nucleotide binding, while the Ala and Thr play a role
in conferring specificity for binding of cAMP or cGMP,
respectively [5]. CNrasGEF mRNA is expressed predomi-
nantly in the brain, with widespread distribution
(Figure 1b). Accordingly, the ~180 kDa CNrasGEF protein
is detected in the brain, including embryonic and adult rat
brain synaptosomes, but not in several fibroblasts cell lines
or HEK-293T cells (Figure 1c). 
We tested the ability of CNrasGEF to bind cAMP
directly. Figure 2a shows that cAMP immobilized on
agarose beads could bind soluble glutathione-S-transferase
(GST)–cNMP-BD of CNrasGEF in vitro, suggesting
direct interactions. Immobilized cAMP also precipitated
full-length CNrasGEF from HEK-293T cells expressing
CNrasGEF, but not from cells expressing CNrasGEF in
which the cNMP-BD was deleted (D cNMP-BD;
Figure 2b). Binding of cAMP to the CNrasGEF cNMP-
BD was also effectively competed by cGMP (data not
shown), suggesting that cGMP can also bind to the CNras-
GEF cNMP-BD. This is consistent with lack of conserva-
tion within the RAA and RTA sequences in the
cNMP-BD described above. The corresponding sequence
in human or Drosophila CNrasGEF is (K/R)GV (see Sup-
plementary material and Figure 2b). Mutating the lysine
to aspartate in the human KGV motif of the CNrasGEF
cNMP-BD (K211D) abolished binding to cAMP
(Figure 2b), whereas an arginine to aspartate mutation in a
RTK sequence just downstream of the KGV motif
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(R215D) had no effect (data not shown). This suggests
that Lys211 is required for cAMP binding to CNrasGEF,
equivalent to the role the arginine of the RAA motif plays
in cAMP binding to PKA [5].
As CNrasGEF contains a CDC25 domain homologous to
those of GEF/GRFs for the Ras and Rap families of small
GTPases, we tested the ability of CNrasGEF to activate
Ras in response to cAMP or cGMP. We expressed FLAG-
tagged CNrasGEF in HEK-293T cells and tested its
ability to activate Ras or Rap1 by a previously described
method [6–8]. We used the following activation-specific
probes for these GTPases: the Ras-binding domain (RBD)
of Raf-1, which specifically binds the active, GTP-bound
form of Ras, and the Rap1-binding domain of Ral-GDS,
which binds the GTP-bound form of Rap1. Expression of
CNrasGEF led to a weak activation of endogenous Ras,
which was greatly enhanced by stimulation of cells with
the membrane-permeable, nonhydrolyzable analogue of
cAMP, 8-Br-cAMP (Figure 3a). This effect was indepen-
dent of PKA activity, because cAMP was still able to stim-
ulate CNrasGEF-mediated activation of Ras in the
presence of H-89 or Rp-8-Br-cAMPS, two known
inhibitors of PKA (Figure 3a). Similarly, 8-Br-cGMP, the
membrane-permeable, non-hydrolyzable analogue of
cGMP, was able to greatly enhance activation of Ras by
CNrasGEF, and this effect was also independent of PKG
activity, as determined by lack of effect of H-8 or Rp-8-Br-
cGMPS, two known inhibitors of PKG (Figure 3b). More-
over, the activation of Ras by CNrasGEF in cells was also
seen following treatment which leads to elevation of intra-
cellular cAMP and cGMP concentrations: forskolin plus
IBMX, or 3-(5¢ -hydroxymethyl-2¢ -furyl)-1-benzylindazole
(YC-1) plus DiPyridamole (DiPy), to elevate intracellular
levels of cAMP or cGMP, respectively (Figure 3c). Thus,
these results suggest that both cAMP and cGMP can stim-
ulate CNrasGEF to activate Ras in living cells. 
To verify that this activation is mediated by the CDC25
domain and is dependent on the cNMP-BD of CNras-
GEF, we performed similar experiments using CNras-
GEF lacking its CDC25 domain (D CDC25) or its
cNMP-BD (D cNMP-BD). As seen in Figure 3d, the 8-Br-
cAMP-mediated activation of Ras via wild-type CNras-
GEF was almost abolished in the D CDC25 or D cNMP-BD
mutants, demonstrating that both domains are required for
the activation of Ras by CNrasGEF in cells. In vitro, we
were unable to demonstrate significant activation of Ras
by the isolated CDC25 domain of CNrasGEF (data not
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Figure 2
Binding of cAMP to the cNMP-BD of CNrasGEF. (a) In vitro binding of
GST–cNMP-BD to immobilized cAMP. cAMP–agarose beads were
incubated with soluble GST–cNMP-BD or GST alone, washed,
proteins separated on 10% SDS–PAGE and immunoblotted with anti-
GST antibodies (upper panel). The lower panel shows the total amount
of proteins incubated with the cAMP beads, on a coomassie blue-
stained gel. (b) Transfected CNrasGEF, but not D cNMP-BD or
CNrasGEF bearing a point mutation (K211D) in the KGV sequence
can be precipitated with cAMP agarose beads. Beads were incubated
with cell lysates from HEK-293T cells expressing wild-type, D cNMP-
BD or K211D CNrasGEF, followed by washing of beads, SDS–PAGE
and immunoblotting with anti-CNrasGEF antibodies (upper panels).
Expression of full-length and mutant CNrasGEF was verified by
immunoblotting aliquots of the respective cell lysates with the same
antibodies (bottom panels). Right and left panels in (b) represent two
separate experiments. 
Figure 1
CNrasGEF domain organization and expression. (a) Schematic
representation of CNrasGEF. The white box in the CDC25 domain
indicates the insert. Sequence alignments of the CDC25, cNMP-BD and
PDZ domains are provided in the Supplementary material. (b) Northern
blot analysis of mRNA from multiple regions of human brain probed with
radiolabeled cDNA corresponding to the 3¢ region of human CNrasGEF.
~7.5 kb and ~8.5 kb transcripts are expressed. (c,d) Western blots
depicting characterization of anti-CNrasGEF antibodies and expression
of the CNrasGEF protein in synaptosomes. Polyclonal anti-CNrasGEF
antibodies were raised against a GST-fusion protein encompassing the
carboxyl terminus (amino acids 1350–1499) of CNrasGEF. These
antibodies recognize the ~180 kDa CNrasGEF protein when
(c) heterologously expressed in HEK-293T cells and epitope-tagged with
HA, FLAG or Myc tags or (d) endogenously expressed in synaptosomes
from adult or embryonic rat brain. No protein was detected with the
pre-immune (pre-imm) serum. IP, immunoprecipitation.
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Figure 3
cAMP/cGMP-mediated activation of Ras by CNrasGEF in living cells.
(a) cAMP-dependent and PKA-independent activation of Ras by
CNrasGEF. HEK-293T cells were transfected (or not) with
FLAG-tagged CNrasGEF, serum-starved overnight and treated with
the indicated compounds (see Supplementary material). Cells were
then lysed and lysate incubated with immobilized RBD of Raf1
(GST–Raf1(RBD)). Co-precipitated activated Ras was then detected
with anti-Ras antibodies (upper panel). The lower two panels depict
the amounts of total endogenous Ras and of the transfected
CNrasGEF (detected with anti-Ras and anti-FLAG antibodies,
respectively). On average, 8-Br-cAMP activated CNrasGEF 9.7-fold,
determined by densitometry (n = 7). (b) cGMP-dependent and
PKG-independent activation of Ras by CNrasGEF. The experiment
was performed as in (a) but using the different compounds indicated.
On average, 8-Br-cGMP activated CNrasGEF 10.4-fold, determined
by densitometry (n = 3). (c) Activation of Ras via CNrasGEF following
elevation of intracellular levels of cAMP or cGMP. Cells were
transfected as in (a), and treated with the indicated compounds.
Parallel treatments with 8-Br-cAMP or 8-Br-cGMP were used as
positive controls. Lysates of treated cells were then incubated with
GST–Raf1(RBD) to precipitate activated Ras as in (a).
(d) Requirement of the cNMP-BD and the CDC25 domain of
CNrasGEF for cAMP-mediated Ras activation. Cells were transfected
with vector alone, wild-type, D cNMP-BD or D CDC25 CNrasGEF, and
then treated (or not) with 8-Br-cAMP. Cell lysates were then
incubated with GST–Raf1(RBD) and treated as in (a). (e) In vitro
activation of Ras by CNrasGEF. Wild-type CNrasGEF, D CDC25
CNrasGEF or GRF2, each FLAG-tagged, were immunoprecipitated
from transfected Hek-293T cells using anti-FLAG antibodies. Equal
amounts of washed immunoprecipitates were incubated with
[ a -32P]GTP plus Ras for 30 min. Bound and unbound radiolabeled
GTP were then separated by filtration and the amount of bound GTP
determined by scintillation counting. Fold Ras activation compared to
the activation of Ras in the absence of GRFs (white) is plotted. The
number of independent experiments (n), in duplicates, is indicated.
(f) cAMP-independent activation of GRF2 in HEK-293T cells. Cells
were transfected with vector alone or with FLAG-tagged GRF2, and
treated (or not) with 8-Br-cAMP. Cell lysate was then incubated with
GST–Raf1(RBD) and processed as in (a). (g) Constitutive,
cAMP-independent but CDC25-dependent activation of Rap1 by
CNrasGEF. HEK-293T cells were transfected with vector alone,
wild-type or D CDC25 CNrasGEF, treated (or not) with 8-Br-cAMP,
and cell lysates incubated with GST–RalGDS(RBD) (upper panel).
Total cellular Rap1 was detected with anti-Rap1 antibodies (middle
panel) and transfected CNrasGEF and the mutant were detected with
anti-FLAG antibodies (lower panel), as above. Autoradiograms are
representative of 2–8 independent experiments. Abbreviations are
listed in the Supplementary material.
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shown), but immunoprecipitated full-length CNrasGEF
(which includes also the REM domain located far
upstream of the CDC25 domain; see Figure 1a) was able
to moderately enhance Ras activation (Figure 3e), with
~2.9-fold activation in 30 minutes; this stimulation was
lost in the D CDC25 mutant (Figure 3e), and was not
further enhanced by in vitro added 8-Br-cAMP (data not
shown), suggesting different mechanism(s) of activation
than that reported for Epac [3]. CNrasGEF-mediated acti-
vation of Ras in vitro was smaller than the 4.4-fold activa-
tion conferred by GRF2, used as a control (Figure 3e).
Unlike CNrasGEF, activation of GRF2 in cells was inde-
pendent of cAMP (Figure 3f), as expected. These results
suggest that in its native conformation in cells, CNrasGEF
becomes strongly active in response to elevated
cAMP/cGMP levels, probably by direct nucleotide
binding, although an indirect effect can not be ruled out.
Ohtsuka et al. [9] recently identified the Rap1 GEF activ-
ity of CNrasGEF, which they termed nRap GEP. In
agreement with their findings, we found that CNrasGEF
can mediate activation of Rap1 in cells via its CDC25
domain, independent of cAMP stimulation (Figure 3g).
Ras is localized at the plasma membrane and activation of
Sos, GRF1/2 and GRP often involves their translocation
from the cytosol to the plasma membrane [10–13].
Immunostaining of CNrasGEF transfected into HEK-
293T cells revealed that it is located at the periphery of
the cell, suggesting that it is targeted to the plasma mem-
brane (see Supplementary material). This localization was
impaired in CNrasGEF lacking the PLPF (GLGF equiva-
lent) sequence but not in cells expressing CNrasGEF
bearing mutations in the PDZ-binding motif (SAV
changed to AAA; see Supplementary material). Thus, the
PDZ domain may be involved in targeting or tethering
CNrasGEF to a PDZ-binding protein associated with the
plasma membrane.
Ras and Rap1 have distinct subcellular localizations and
interact with an overlapping set of effector proteins [14].
We conclude that CNrasGEF can activate both Rap1 and
Ras, but only the activation of Ras, not of Rap1, is stimu-
lated by binding of cAMP or cGMP; thus, elevation of
intracellular cAMP or cGMP levels can cause a switch
from Rap1 to Ras activation by CNrasGEF. In view of its
strong expression in brain and synaptosomes, its activa-
tion by cyclic nucleotides, and the presence of a PDZ
domain, we anticipate that either a plasma membrane
protein such as a G-protein-coupled receptor that causes
elevation of cAMP upon activation, or an ion channel
enriched in synaptosomes (several of which possess a
PDZ-binding motif) could be a candidate activator of
CNrasGEF. The presence of CNrasGEF near or even in
complex with such proteins could lead to a direct connec-
tion between them and Ras/Rap1 activation. CNrasGEF
was identified in this study as a Nedd4-interacting
protein, and our recent work has detected Nedd4 at the
plasma membrane and in endosomes (P. Plant, F. LaFont,
K. Simons and D.R., unpublished observations). This
could provide a mechanism to regulate CNrasGEF inter-
actions with Ras at the plasma membrane and Rap1 in
endosomes. Finally, the association with Nedd4 may
allow regulation of stability of CNrasGEF (or associated
proteins) by ubiquitination.
Supplementary material
Supplementary material including CNrasGEF cellular localization,
sequence alignments of various domains of CNrasGEF with related
proteins and additional methodological details is available at
http://current-biology.com/supmat/supmatin.htm.
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